

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Non-Preferred Nasal Corticosteroids

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Strength	Quantity Limit
<u>Preferred</u>		
OTC fluticasone propionate (Aller-Flo, Clarispray, Flonase Allergy Relief, Children's Flonase Allergy Relief and all other commercially available OTC fluticasone propionate agents)	50mcg/actuation	1 inhaler/30 days
OTC triamcinolone acetonide (Nasacort OTC, Children's Nasacort, Nasal Allergy Spray and all other commercially available OTC triamcinolone acetonide agents)	55mcg/actuation	1 inhaler/30 days
<u>Non-Preferred</u>		
prescription budesonide (Rhinocort Aqua)	32 mcg/actuation	2 inhalers/30 days
OTC budesonide	32 mcg/actuation	2 inhalers/30 days
OTC Rhinocort Allergy	32 mcg/actuation	2 inhalers/30 days
Beconase AQ (beclomethasone)	42 mcg/actuation	2 inhalers/30 days
Flonase Sensimist, Children's Flonase Sensimist (fluticasone furoate)	27.5mcg/actuation	1 inhaler/30 days
flunisolide	25mcg/actuation	3 inhalers/30 days
prescription fluticasone	27.5mcg/actuation	1 inhaler/30 days
mometasone (Nasonex)*	50 mcg/actuation	1 inhaler/30 days
Omnaris (ciclesonide)	50 mcg/actuation	1 inhaler/30 days
QNASL (beclomethasone dipropionate)	80mcg/actuation	1 inhaler/30 days

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Qnasl Children's	40mcg/actuation	1 inhaler/30 days
prescription triamcinolone	55 mcg/actuation	1 inhaler/30 days
Veramyst (fluticasone furoate)	27.5 mcg/actuation	1 inhaler/30 days
Xhance (fluticasone)	93 mcg/actuation	2 inhalers/30 days
Zetonna (ciclesonide)	37mcg/actuation	1 inhaler/30 days

*Nasonex brand or generic (mometasone) for the treatment of nasal polyps: may approve two (2) inhalers per 30 days.

APPROVAL CRITERIA

Requests for non-preferred nasal corticosteroid agents may be approved if the following criteria are met:

- I. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response or intolerance to two preferred nasal corticosteroids;

Preferred nasal corticosteroid agents: OTC fluticasone propionate (Aller-Flo, Clarispray, Flonase Allergy Relief, Children's Flonase Allergy Relief and all other commercially available OTC fluticasone propionate agents), OTC triamcinolone acetonide (Nasacort OTC, Children's Nasacort, Nasal Allergy Spray and all other commercially available OTC triamcinolone acetonide agents).

Non-preferred nasal corticosteroid agents: prescription budesonide (Rhinocort Aqua), OTC budesonide, OTC Rhinocort Allergy, Beconase AQ (beclomethasone), Flonase Sensimist, Children's Flonase Sensimist, flunisolide, prescription fluticasone, mometasone (Nasonex), Omnaris, QNASL, Qnasl Children's, prescription triamcinolone, Veramyst, Xhance, Zetonna.

OR

- II. One of the following:

- A. Prescription fluticasone (generic Flonase) may be approved for individuals requesting for non-allergic rhinitis; **OR**
- B. Prescription or OTC budesonide may be approved for individuals who are pregnant; **OR**
- C. Mometasone may be approved for individuals requesting for nasal polyps;

OR

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

- III. Requests for Xhance (fluticasone propionate) may be approved for individuals who meet the following criteria in addition to (I.) above:
- A. Individual is 18 years of age or older; AND
 - B. Individual has a diagnosis of bilateral nasal polyps; AND
 - C. Individual has associated moderate to severe nasal congestion.

Xhance (fluticasone propionate) may **not** be approved for the following:
 Concurrent use with a strong CYP3A4 inhibitor (such as but not limited to, ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin, conivaptan, lopinavir, or voriconazole).

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: June 5, 2018.

DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.